Please login to the form below

Not currently logged in
Email:
Password:

Amgen aspires to new Kyprolis label in the US and Europe

Appeals to regulators to add survival data to multiple myeloma drug's labelling

Amgen

After a tumultuous beginning Amgen’s Kyprolis has started to pick up the pace, and the multiple myeloma drug could be in-line for stronger labelling after the release of positive phase III data.

The ASPIRE trial looked at patients with relapsing or hard-to-treat multiple myeloma and compared Kyprolis (carfilzomib) with lenalidomide and dexamethasone (Rd) to Rd alone.

Newly-released analysis show Kyprolis exceeded its secondary endpoint of overall survival, reducing the risk of death by 21% over Rd alone. Patients in the trial received 18 cycles of Kyprolis with Rd administered twice-weekly at 27 mg.

Shortly after releasing the results Amgen filed applications with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to add this overall survival data to Kyprolis’ label.

Earlier this year Amgen received more positive results from its ENDEAVOR trial showing the two proteasome inhibitors outperformed Takeda’s Velcade (bortezomib) in relapsed myeloma patients for progression-free survival.

The previous data also proved similar to its newly-released ASPIRE trial.  Patients on the Kyprolis regimen at 56 mg in combination with Rd reduced the risk of death by 21% over Velcade and dexamethasone (Vd) and lived 7.6 months longer than those treated with Vd.

Kyprolis is already approved in the US and EU on the basis of primary analysis of progression-free survival (PFS) in the ASPIRE study.

The drug is also approved in the US as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.

Article by
Gemma Jones

17th July 2017

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...
Top 10 Tips for Optimizing Asynchronous Virtual Meetings
Natalie Yeadon shares her expertise on how you can make the most out of your asynchronous virtual meetings and ask effective questions virtually....

Infographics